Skip to content

The Effectiveness of IV/PO Acetaminophen in the Perioperative Period in Reducing Opiate Use After Lumbar Spine Fusion

The Effectiveness of IV/PO Acetaminophen in the Perioperative Period in Reducing Opiate Use After Lumbar Spine Fusion: a Prospective, Randomized Controlled Trial

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03104816
Enrollment
28
Registered
2017-04-07
Start date
2016-10-31
Completion date
2017-12-31
Last updated
2019-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fusion of Spine, Lumbar Region

Keywords

Acetaminophen po, Acetaminophen IV, Pain management, minimally invasive lumbar fusions, Ofirmev, Analgesics, Opioid, Pain, Postoperative, Spinal

Brief summary

Simple explanation and rationale: Recovery after spine surgery is usually accompanied by severe pain which has traditionally been managed with opioids. It is common practice to supplement opioid treatment with different classes of analgesics which work through alternative pain pathways and receptors in order to achieve an additive or synergistic effect while reducing the amount of opioids necessary for pain control. Acetaminophen can be a beneficial supplemental analgesic to opioids for postoperative pain relief. Intervention: Patients will be randomized to either the treatment with IV acetaminophen (A), PO acetaminophen (B), or hydromorphone control group (C). Objective/Purpose: Primary objective is to determine the impact of administering a supplemental non-opioid analgesic drug such as IV or PO acetaminophen on total opioid dose administered over the postoperative period. Secondary objectives include investigating the impact of IV/PO acetaminophen on the level of postoperative pain, patient satisfaction, and side effects secondary to opioids such as nausea, vomiting, pruritus, sedation, respiratory depression, ileus, and urinary retention, and PACU (postoperative care unit) discharge time. Study population: 126 patients will be enrolled in the study (42 for group A, 42 for group B, and 42 for control group C). Follow-up and Endpoints / Outcomes: Postoperative assessments will be done at 0, 30, and 60 minutes, 6 hours, 12 hours and 24 hours after surgery. Patients will be evaluated for pain (using a numeric rating scale), total opioid consumption, and for opioid side effects including drowsiness (using the Ramsey sedation scale and the Aldrete score at the time of arrival to and discharge from recovery room), respiratory depression, nausea, vomiting, and pruritus. Patient satisfaction will also be assessed using a numeric rating scale.

Detailed description

Simple explanation and rationale: Recovery after spine surgery, especially spinal fusion surgery, is usually accompanied by severe pain which has traditionally been managed with opioids. While opioids have been proven effective, they are associated with undesirable side effects including nausea, vomiting, pruritus, sedation, respiratory depression, ileus, and urinary retention leading to increased time required in recovery and a decrease in patient satisfaction. For this reason, it is common practice to supplement opioid treatment with different classes of analgesics which work through alternative pain pathways and receptors in order to achieve an additive or synergistic effect while reducing the amount of opioids necessary for pain control. Acetaminophen is a centrally-acting cyclooxygenase inhibitor nonsteroidal anti-inflammatory medication that has minimal, if any, gastrointestinal and platelet-inhibiting side effects, and is better tolerated by patients than other cyclooxygenase inhibitors. This medication can be a beneficial supplemental analgesic to opioids for postoperative pain relief. Previously conducted studies demonstrate a rationale for the use of intravenous/PO acetaminophen in a multimodal analgesic regimen to reduce postoperative analgesia. Intervention: Patients will be randomized to either the treatment with IV acetaminophen (A), PO acetaminophen (B), or hydromorphone control group (C). Patients who are randomized to group A will receive 1 g of IV acetaminophen during the wound closure and every 4 to 6 hours postoperatively for a total of 4 g in 24 hours. Patients who are randomized to group B will receive 1 g of PO acetaminophen before surgery and every 4 to 6 hours postoperatively for a total of 4 g in 24 hours. Patients who are randomized to control group C will not receive acetaminophen. Post-operatively, patients in both groups will also receive IV hydromorphone PCA (patient-controlled analgesia) only for 24 hours for pain. Objective/Purpose: Primary objective is to determine the impact of administering a supplemental non-opioid analgesic drug such as IV or PO acetaminophen on total opioid dose administered over the postoperative period. Secondary objectives include investigating the impact of IV/PO acetaminophen on the level of postoperative pain, patient satisfaction, and side effects secondary to opioids such as nausea, vomiting, pruritus, sedation, respiratory depression, ileus, and urinary retention, and PACU discharge time. Study population: 126 patients will be enrolled in the study (42 for group A, 42 for group B, and 42 for control group C). Follow-up and Endpoints / Outcomes: Postoperative assessments will be done at 0, 30, and 60 minutes, 6 hours, 12 hours and 24 hours after surgery. Patients will be evaluated for pain (using a numeric rating scale), total opioid consumption, and for opioid side effects including drowsiness (using the Ramsey sedation scale and the Aldrete score at the time of arrival to and discharge from recovery room), respiratory depression, nausea, vomiting, and pruritus. Patient satisfaction will also be assessed using a numeric rating scale. Statistics: All sample size calculations with reference to: * Specific Aim 1 reduction of opioid intake by at least 25% between the Control (Group C) and Intervention Groups A and B, and * Specific Aim 2 improvement of Pain Score by at least 25% between the Control (Group C) and the Intervention Groups A and B,

Interventions

DRUGAcetaminophen IV Soln 10 MG/ML
DRUGAcetaminophen
DRUGHydromorphone

Sponsors

University of Southern California
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* ASA (American Society of Anesthesiologists) I-III patients scheduled for elective one or two level minimally invasive lumbar fusions

Exclusion criteria

* Patients requiring surgery for neoplastic processes * Allergy to acetaminophen * Liver dysfunction and elevated Liver Function Tests (LFTs) * Alcohol or drug dependency * Mental retardation * Less than 50 kg of weight * regnant women * Patients requiring long-acting opioid pain management (including fentanyl patch, oxycontin, etc) for over 3 weeks immediately prior to surgery

Design outcomes

Primary

MeasureTime frameDescription
Postoperative Opioid UseWithin 24 hours after surgeryDetermine the impact of administering a supplemental non-opioid analgesic drug such as IV/oral acetaminophen on total opioid dose administered over the perioperative period.

Countries

United States

Participant flow

Recruitment details

28 patients were involved in study. 22 patients completed the study. Patients were recruited in the surgical clinic, preoperative clinic, preoperative surgical area.

Pre-assignment details

Patients were included in the study according to their inclusion and exclusion criteria. There were no patients were excluded from study in the period after signing the consent to assignment to groups.

Participants by arm

ArmCount
Acetaminophen IV Soln 10 MG/ML (A)
Patients in group A will receive 1 g of IV acetaminophen 15 minutes prior to wound incision, and every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours. Acetaminophen IV Soln 10 MG/ML Hydromorphone
9
PO Acetaminophen (B)
Patients in group B will receive 1 g of PO acetaminophen prior to surgery, and 1 g of oral acetaminophen every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours. Acetaminophen Hydromorphone
9
Hydromorphone (Control Arm) (C)
Patients in the control arm (Group C) will not receive acetaminophen for 24 hours. Hydromorphone
4
Total22

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyLack of Efficacy020
Overall StudyProtocol Violation202

Baseline characteristics

CharacteristicAcetaminophen IV Soln 10 MG/ML (A)PO Acetaminophen (B)Hydromorphone (Control Arm) (C)Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
6 Participants4 Participants1 Participants11 Participants
Age, Categorical
Between 18 and 65 years
3 Participants5 Participants3 Participants11 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants2 Participants0 Participants3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
8 Participants7 Participants4 Participants19 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Number of analyzed participants in each group9 Participants9 Participants4 Participants22 Participants
Region of Enrollment
United States
9 participants9 participants4 participants22 participants
Sex: Female, Male
Female
5 Participants9 Participants1 Participants15 Participants
Sex: Female, Male
Male
4 Participants0 Participants3 Participants7 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 80 / 80 / 4
other
Total, other adverse events
0 / 80 / 80 / 4
serious
Total, serious adverse events
0 / 80 / 80 / 4

Outcome results

Primary

Postoperative Opioid Use

Determine the impact of administering a supplemental non-opioid analgesic drug such as IV/oral acetaminophen on total opioid dose administered over the perioperative period.

Time frame: Within 24 hours after surgery

ArmMeasureGroupValue (MEAN)Dispersion
Acetaminophen IV Soln 10 MG/ML (A)Postoperative Opioid UsePACU dose1.2 mgStandard Deviation 0.4
Acetaminophen IV Soln 10 MG/ML (A)Postoperative Opioid UseWard dose9.8 mgStandard Deviation 2.9
PO Acetaminophen (B)Postoperative Opioid UsePACU dose1.3 mgStandard Deviation 0.3
PO Acetaminophen (B)Postoperative Opioid UseWard dose10.4 mgStandard Deviation 3.1
Hydromorphone (Control Arm) (C)Postoperative Opioid UsePACU dose1.7 mgStandard Deviation 0.5
Hydromorphone (Control Arm) (C)Postoperative Opioid UseWard dose13 mgStandard Deviation 5.5

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026